CRSP CRISPR: Company Short-Term Debt

Corporate company logo of CRISPR Therapeutics Inc (CRSP)

Can CRISPR Therapeutics AG (CRSP) monetize the high cost of gene therapy amidst the complexities of insurance payouts? The answer lies in its ownership of patents for the CRISPR/Cas9 method and the success of the drug Casgevy. Short-term debt financing confirms liquidity despite the costs of cryogenic delivery of biomaterials, and the current level is 0.00, which characterizes the issuer's current debt load.

CRSP (CRISPR Therapeutics) Short-Term Debt Volume history from 07/04/2022 to 11/01/2026

Comprehensive metric breakdowns and analytics for CRISPR (CRSP)

- stock price and consensus target price:
Stock Price CRISPR Therapeutics|CRSP - Consensus Target
- company stock capitalization data:
Market Value CRISPR Therapeutics AG|CRSP - Value Adjusted for Debt and Cash
- shareholders' equity book value data:
Book Value per Share CRISPR Therapeutics|CRSP - Book Valuation of Business|Market Value to Book Value Ratio crisprtx.com|CRSP - Company Total Asset Base
- debt obligations and liquidity statistics:
Debt to Equity CRISPR Therapeutics AG|CRSP - Long-Term Liabilities to Equity|Short-Term Debt to Equity CRISPR Therapeutics AG|CRSP - Aggregate Debt Obligations|Debt to Book Value CRISPR Therapeutics AG|CRSP - Company Long-Term Loans and Borrowings|Company Current Liabilities CRISPR Therapeutics|Quick Ratio crisprtx.com
- net income and valuation multiples indicators:
CRSP - Final Profit
General company analysis:CRISPR Therapeutics - CRSP
Mass-produced product of CRISPR Therapeutics AG

Monitoring liquidity is critical for finding fundamental support in CRISPR Therapeutics AG (CRSP), which is entering the market with a revolutionary treatment for blood diseases. By analyzing the level of current liabilities, an investor assesses the amount of debt maturing within one year, which allows for the determination of working capital deficit risks and confirms the financial stability of CRISPR Therapeutics AG (CRSP) during the commercialization of its genetic technologies.

Competing companies

Tempus AI, Inc - Company Short-Term Debts|Qiagen NV (QGEN) - Company Current Liabilities|Ionis Pharma (IONS) - Company Short-Term Debt|Repligen Inc. - Company Short-Term Loans and Borrowings|RNA (Avidity Biosciences) - Company Short-Term Debts|genedx.com (WGS) - Short-Term Debt Volume|Company Short-Term Debt Ultragenyx (RARE)|Short-Term Debt Volume Beam Therapeutics Inc|Company Short-Term Debt Sarepta Therapeutics Inc SRPT|TWST (Twist Bioscience Corp) - Current Liabilities|TXG - Company Short-Term Debt|Company Short-Term Loans and Borrowings NTLA (intelliatx.com)|STOK (Stoke Therapeutics, Inc.) - Company Current Liabilities|BioLife Solutions Inc - Company Short-Term Loans and Borrowings|Company Current Liabilities WVE|MAZE (Maze Therapeutics Corp) - Amount of Current Liabilities|Company Short-Term Debts SION|PRME (primemedicine.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts TSHA (Taysha Gene Therapies, Inc.)|uniQure NV (QURE) - Short-Term Debt|MGTX - Company Short-Term Debt|Company Short-Term Loans and Borrowings RGNX (REGENXBIO Corp)|SLDB: Company Short-Term Debts|ocugen.com (OCGN) - Company Short-Term Debts|Company Short-Term Debt PacBio|Benitec Biopharma Inc - Current Liabilities|Company Short-Term Debts DSGN|RCKT - Short-Term Debt|4D Molecular Therapeutics - Company Current Liabilities|Company Short-Term Debts Lexeo Therapeutics Inc. LXEO|KRRO: Company Current Liabilities|Editas Medicine Inc - Amount of Current Liabilities|SLN: Company Short-Term Debts|PRQR - Short-Term Debt Volume|CDXS (Codexis Inc) - Company Short-Term Debts|Company Current Liabilities sangamo.com (SGMO)|Company Short-Term Debt Nautilus Biotechnology (NAUT)|Short-Term Debt Volume Metagenomi Inc.|Precision BioSciences - Company Current Liabilities|Company Short-Term Loans and Borrowings GBIO|Boundless Bio, Inc. - Company Short-Term Debts|XCUR - Company Short-Term Debts|IMNN: Company Short-Term Debts|Short-Term Indebtedness Phio Pharmaceuticals Corp. PHIO|MBIO (Mustang Bio Inc) - Company Short-Term Debts|Company Current Liabilities TransCode (RNAZ)|Company Short-Term Debt Bionano Genomics, Inc. (BNGO)|APDN (adnas.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt bluebird bio BLUE|Short-Term Debt Volume ImmunoPrecise Antibodies Ltd (IPA)|OMGA - Company Short-Term Debt|Current Liabilities OMIC|RGLS: Company Short-Term Debts|Company Short-Term Indebtedness SYRS|Company Short-Term Debt Telesis Bio|Company Short-Term Indebtedness TCON (TRACON Pharmaceuticals Inc.)|Company Short-Term Debts UBX